Merz
Merz Therapeutics is a specialty pharmaceutical company that develops and distributes treatments in neurology (including the Xeomin botulinum toxin franchise for movement disorders), dermatology, and general health, selling through regulated professional channels to healthcare providers across 15+ countries in Europe, the Middle East, and North America.
- Company typePrivate
- Founded1909
- HeadquartersAllschwil, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Merz does
Merz Therapeutics is a specialty pharmaceutical company operating across three therapy areas — Neurology, Dermatology, and Health — with a primary focus on movement disorders, neurological diseases, and dermatological conditions. The company's flagship product, Xeomin, is a botulinum toxin used in the treatment of neurological conditions and movement disorders, distributed through regulated pharmaceutical channels to healthcare professionals. Merz traces its origins to 1908/1909, and the group maintains a multi-regional commercial footprint with country-specific websites and operations across 14+ European markets (Austria, Belgium, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, the Nordics, UK/Ireland, and Russia), the Middle East (Saudi Arabia), and North America (United States).
The Swiss business is organized under the legal entity Merz Pharma (Schweiz) AG, a private limited company domiciled at Hegenheimermattweg 57, 4123 Allschwil, Switzerland. The Swiss arm runs a gated professional portal — the Fachportal Neurologie (fachportal-neurologie.merz.ch) — that restricts access to product information to medical professionals holding a verified Swiss-Rx account, reflecting a tightly controlled, sales-led go-to-market model built around regulated pharmaceutical distribution rather than direct-to-consumer channels. Product marketing is supported through a multilingual corporate website (German and French for Switzerland), LinkedIn, and Facebook for professional engagement.
Merz's revenue model is the sale of pharmaceutical products through medical professional and pharmacy channels, with pricing not publicly disclosed and product information gated behind Swiss-Rx authentication for healthcare providers. The company is privately held with no public ticker, has not disclosed funding rounds, acquisitions, or leadership-team data in the available material, and positions itself around 117 years of pharmaceutical innovation, a patient-centered approach, and a horizontal segmentation strategy spanning its three therapy verticals.
Merz firmographics
Firmographics- Name
- Merz
- Legal name
- Merz Pharma (Schweiz) AG
- Website
- https://merz.ch
- Company type
- Private
- Founded year
- 1909
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Merz Therapeutics is a specialty pharmaceutical company that develops and distributes treatments in neurology (including the Xeomin botulinum toxin franchise for movement disorders), dermatology, and general health, selling through regulated professional channels to healthcare providers across 15+ countries in Europe, the Middle East, and North America.
- Ownership category
- akta.pro rank
Merz industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
Keywords
Where Merz is headquartered
LocationHeadquarters
- HQ city
- Allschwil
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Merz business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Products: Merz Therapeutics generates revenue through development and sale of pharmaceutical products in neurology (movement disorders, neurological diseases), dermatology, and general health segments. Products are distributed through medical professional portals requiring Swiss-Rx authentication for healthcare providers.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Merz product offering
Product offeringCore offering
Merz Therapeutics develops, manufactures, and distributes prescription pharmaceutical products in three therapeutic areas: Neurology (treatment of movement disorders and neurological diseases, including the botulinum toxin product Xeomin), Dermatology (skin condition treatments), and Health/Gesundheit (general health and wellness therapies). Products are delivered to patients through medical professionals via a Swiss-Rx authenticated professional portal and regional pharmaceutical distribution networks across Europe, the Middle East, and North America.
Product overview
Merz Therapeutics is a pharmaceutical company with 117 years of history (founded circa 1908) operating across three therapeutic areas: Neurology (neurological diseases and movement disorders), Dermatology (skin conditions), and Gesundheit/Health (general health complaints). The company operates as a unified pharmaceutical therapeutics division offering prescription medications and healthcare solutions through its regional Merz Pharma subsidiaries, including Merz Pharma (Schweiz) AG in Switzerland. Products include Xeomin (botulinum toxin for neurological conditions) within the neurology portfolio, along with dermatology and general health product lines. The company emphasizes patient-centered innovation and maintains regional operations across Europe, Middle East, and North America.
Differentiator
Problem solved
Functional benefit
Brands
- Merz Therapeutics: Therapeutic innovations company focused on better outcomes for patients in Neurology, Dermatology, and Health sectors.
Products and services
- Xeomin A botulinum toxin product for the treatment of neurological conditions, including movement disorders. Distributed through the Merz Therapeutics neurology portfolio and accessible to medical professionals via the Swiss-Rx authenticated Fachportal.
- Neurology Portfolio Therapeutic solutions for patients suffering from movement disorders and neurological diseases, focused on improving quality of life. Includes Xeomin and related neurology products.
- Dermatology Portfolio Dermatological pharmaceutical treatments addressing skin conditions and health complaints to improve patient outcomes.
- Gesundheit (Health) Portfolio Healthcare products focused on general health complaints and patient wellness, addressing conditions outside the core neurology and dermatology franchises.
Companies that use Merz
Customer profileSegments3 records
Ideal customer profiles1 record
Merz technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Merz partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
Merz competitors and assessment
Company assessmentBroad incumbents
- Novartis: Swiss-headquartered pharma incumbent with broad neurology and dermatology exposure; comparable as a Switzerland-based pharma employer and HCP engagement partner, though vastly larger in scale.
- UCB: European-headquartered specialty pharma with neurology and immunology franchises, comparable in geographic mix and specialty-pharma commercial model to Merz.
- Lundbeck: CNS-focused specialty pharma with movement-disorder and neurology expertise, overlapping with Merz Therapeutics' neurology franchise and HCP target audience.
Direct peers
- Galderma: Specialty pharma focused on dermatology and aesthetics, overlapping with Merz's dermatology portfolio and broader physician-channel strategy in skin health.
- AbbVie (Allergan Aesthetics): Markets Botox, the global category-leading botulinum toxin and Xeomin's principal direct competitor across both therapeutic neurology and aesthetics indications.
- Hugel: Korean specialty biopharmaceutical company with botulinum toxin (Botulax/Letybo) and dermatology aesthetics products competing globally with Xeomin.
- Supernus Pharmaceuticals: U.S. specialty pharma focused on CNS including movement disorders, with a similar physician-channel commercialization model to Merz Therapeutics.
- Ipsen: Markets Dysport/Azzalure, the other major botulinum toxin brand, competing head-to-head with Xeomin in movement disorders and aesthetics.
Emerging players
- Revance Therapeutics: Develops DaxibotulinumtoxinA and aesthetic dermatology franchises, addressing the same neurology/aesthetics prescriber base as Merz with next-generation toxin candidates.
- Evolus: Aesthetics-focused challenger with Jeuveau (prabotulinumtoxinA), competing in the same botulinum toxin category as Xeomin, particularly in the U.S. aesthetics segment.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Merz social profiles
Digital presenceMerz financial estimates
Financial estimateRevenue estimate
Valuation estimate
Merz leadership team
Management profileNumber of profiles
Merz subsidiaries and ownership
Company hierarchySubsidiaries3 records
Merz funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Merz M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Merz
What does Merz do?
Merz Therapeutics develops, manufactures, and distributes prescription pharmaceutical products in three therapeutic areas: Neurology (treatment of movement disorders and neurological diseases, including the botulinum toxin product Xeomin), Dermatology (skin condition treatments), and Health/Gesundheit (general health and wellness therapies). Products are delivered to patients through medical professionals via a Swiss-Rx authenticated professional portal and regional pharmaceutical distribution networks across Europe, the Middle East, and North America.
Is Merz a public or private company?
Merz is a private company. It is classified as unknown and is currently operating.
When was Merz founded?
Merz was founded in 1909. It employs 51 to 100 people.
Where is Merz based?
Merz is headquartered in Allschwil, Switzerland, in the Europe region.
How does Merz make money?
One revenue line is on record: pharmaceutical Products.
Who are Merz's main competitors?
Broad incumbents on record are Novartis, UCB and Lundbeck. Direct peers are Galderma, AbbVie (Allergan Aesthetics), Hugel, Supernus Pharmaceuticals and Ipsen. Emerging players are Revance Therapeutics and Evolus.
Does Merz have an API?
No public API is recorded for Merz.
What industry is Merz in?
Merz's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.